Initiate additional MARITIME Phase 3 studies of maridebart cafraglutide across multiple indications
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 May 2025
- Due
- 31 Dec 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planning for additional MARITIME Phase 3 studies across multiple indications remains on track with additional studies expected to initiate throughout 2025.”
What we found
Evidence strength A What the grades mean
The FY2025 10-K reports six MariTide Phase 3 studies initiated in 2025, including new cardiovascular, heart failure and sleep apnea studies beyond weight management.
-
A Amgen Inc. 8-K filed 2026-02-03
“MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes, is enrolling adults living with established atherosclerotic cardiovascular disease and obesity or overweight.” ✓ confirmed on the page
-
A Amgen Inc. 10-K filed 2026-02-13
“We also advanced our innovative pipeline, including the initiation of six global Phase 3 clinical studies for MariTide” ✓ confirmed on the page
-
A Amgen Inc. 10-K filed 2026-02-13
“as six programs initiated Phase 3 studies” ✓ confirmed on the page
Market reaction: the shares moved +9.3% against the S&P 500 over the three sessions around the disclosure (2 Feb 2026 to 5 Feb 2026). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Additional MARITIME Phase 3 studies of MariTide
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Amgen Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-AMGN-005966 · Corrections policy